{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Enzyme+Inhibitors",
    "query": {
      "condition": "Enzyme Inhibitors"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 93,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Enzyme+Inhibitors&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T01:10:31.454Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01231620",
      "title": "A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "Zanamivir",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match zanamivir",
          "type": "DRUG"
        },
        {
          "name": "Oseltamivir",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match oseltamivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 626,
      "start_date": "2011-01-15",
      "completion_date": "2015-03-18",
      "has_results": true,
      "last_update_posted_date": "2018-10-15",
      "last_synced_at": "2026-06-11T01:10:31.454Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01231620"
    },
    {
      "nct_id": "NCT00321945",
      "title": "A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation",
        "Atrial Flutter"
      ],
      "interventions": [
        {
          "name": "ACE-Inhibitors and Angiotensin Receptor Blockers",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 546,
      "start_date": "2005-12",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2013-09-27",
      "last_synced_at": "2026-06-11T01:10:31.454Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Decatur, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00321945"
    },
    {
      "nct_id": "NCT03569631",
      "title": "A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fragile X Syndrome",
        "FXS",
        "Fra(X) Syndrome"
      ],
      "interventions": [
        {
          "name": "BPN14770",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tetra Discovery Partners",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2018-07-09",
      "completion_date": "2020-07-31",
      "has_results": true,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-06-11T01:10:31.454Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03569631"
    },
    {
      "nct_id": "NCT01278173",
      "title": "A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Adult Refractory Complex Partial Seizures"
      ],
      "interventions": [
        {
          "name": "Sabril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lundbeck LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2010-12",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2016-06-07",
      "last_synced_at": "2026-06-11T01:10:31.454Z",
      "location_count": 22,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Dover, Delaware + 19 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Dover",
          "state": "Delaware"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01278173"
    },
    {
      "nct_id": "NCT04467931",
      "title": "ACEI or ARB and COVID-19 Severity and Mortality in US Veterans",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypertension",
        "COVID"
      ],
      "interventions": [
        {
          "name": "ACEI/ARB",
          "type": "DRUG"
        },
        {
          "name": "Non-ACEI/ARB",
          "type": "DRUG"
        },
        {
          "name": "ACEI",
          "type": "DRUG"
        },
        {
          "name": "ARB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22213,
      "start_date": "2020-01-19",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-04-28",
      "last_synced_at": "2026-06-11T01:10:31.454Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04467931"
    },
    {
      "nct_id": "NCT00672451",
      "title": "Rhubarb and Angiotensin Converting Enzyme Inhibitor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "rhubarb extract",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Wake Forest University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2008-01",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2018-12-13",
      "last_synced_at": "2026-06-11T01:10:31.454Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00672451"
    },
    {
      "nct_id": "NCT01919801",
      "title": "Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Angiotensin Converting Enzyme Inhibitor Induced Angioedema"
      ],
      "interventions": [
        {
          "name": "Icatibant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2013-12-02",
      "completion_date": "2015-08-22",
      "has_results": true,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-06-11T01:10:31.454Z",
      "location_count": 43,
      "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Gainesville, Florida + 31 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01919801"
    },
    {
      "nct_id": "NCT04722887",
      "title": "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alpha1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Alpha-1 15%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Liquid Alpha1-Proteinase Inhibitor (Human)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 17,
      "start_date": "2021-08-13",
      "completion_date": "2025-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-12",
      "last_synced_at": "2026-06-11T01:10:31.454Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04722887"
    },
    {
      "nct_id": "NCT02252159",
      "title": "Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "MPN (Myeloproliferative Neoplasms)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2544,
      "start_date": "2014-07-31",
      "completion_date": "2019-08-03",
      "has_results": false,
      "last_update_posted_date": "2021-04-26",
      "last_synced_at": "2026-06-11T01:10:31.454Z",
      "location_count": 264,
      "location_summary": "Green Valley, Arizona • Safford, Arizona • Scottsdale, Arizona + 261 more",
      "locations": [
        {
          "city": "Green Valley",
          "state": "Arizona"
        },
        {
          "city": "Safford",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02252159"
    },
    {
      "nct_id": "NCT00446862",
      "title": "The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry Disease",
        "Proteinuria"
      ],
      "interventions": [
        {
          "name": "enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "19 Years to 85 Years"
      },
      "enrollment_count": 36,
      "start_date": "2007-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-06-11T01:10:31.454Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00446862"
    }
  ]
}